Stock Screener App

무료 -

설치하다

17.14

4.14% -0.74

시장 영업 전: 18.40 1.26 +7.35%

First Tracks Biotherapeutics Inc (TRAX)

개요 뉴스 가격 이력 토론 예측

First Tracks Biotherapeutics Inc 주식(TRAX)의 최신 뉴스

[Form 4/A] First Tracks Biotherapeutics, Inc. Amended Insider Trading Activity - Stock Titan

First Tracks Biotherapeutics (TRAX) director receives stock options and RSU grant - Stock Titan

First Tracks Biotherapeutics (TRAX) awards options and RSUs to director - Stock Titan

Director at First Tracks Biotherapeutics (TRAX) gets equity awards - Stock Titan

First Tracks Biotherapeutics (TRAX) director awarded options and RSUs - Stock Titan

H.C. Wainwright initiates AnaptysBio stock coverage with buy rating - Investing.com UK

H.C. Wainwright initiates AnaptysBio stock coverage with buy rating By Investing.com - Investing.com Canada

TRAX Initiated Coverage by First Tracks -- Rating Set to Overwei - GuruFocus

Wells Fargo Initiates First Tracks Biotherapeutics at Overweight - Moomoo

AnaptysBio earnings up next: First report as royalty company - Investing.com

TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC

AnaptysBio Details Tax Treatment of Spin-Off Dividend - TipRanks

Spin-off dividend tax info posted by AnaptysBio (NASDAQ: ANAB) - Stock Titan

First Tracks Biotherapeutics (TRAX) Stock Price, News & Analysis $TRAX - MarketBeat

J.P. Morgan Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Cuts Target Price to $30 - Moomoo

First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences - Sahm

Zumiez Inc. to Report Fiscal 2026 First Quarter Results - The Manila Times

First Tracks Biotherapeutics (TRAX) Stock Forecast and Price Target 2026 $TRAX - MarketBeat

Autoimmune drug biotech First Tracks to meet investors at Jefferies, Leerink - Stock Titan

TRAXV SEC FilingsFirst Tracks Biotherapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

First Tracks Biotherapeutics, Inc.Ordinary Shares (NQ: TRAX - FinancialContent

AnaptysBio (ANAB) Valuation After Spin Off And Shift To Royalty Focused Model - Sahm

First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares; issuer gets no proceeds - Stock Titan

Emily Bodnar Reiterates Buy on AnaptysBio, Keeps $30 Price Target on ANB033 Progress and Solid Cash Runway - TipRanks

TRAX SEC FilingsFirst Tracks Biotherapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

How The Grupo Traxión (BMV:TRAXION A) Story Is Shifting With Cautious New Analyst Targets - Yahoo Finance

Form 424B3 First Tracks Biotherapeu - StreetInsider

First Tracks Biotherapeutics (NASDAQ: TRAX) registers 10.5M resale shares - Stock Titan

First Tracks Biotherapeutics 1Q 2026: Net loss $(50.5M), Revenue $0— 10-Q Summary - TradingView

[Form 4] First Tracks Biotherapeutics, Inc. Insider Trading Activity - Stock Titan

First Tracks Biotherapeutics (NASDAQ: TRAX) details Q1 loss and major post spin-off cash raises - Stock Titan

First Tracks Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update - The Manila Times

[8-K] First Tracks Biotherapeutics, Inc. Reports Material Event - Stock Titan

Director at First Tracks Bio (NASDAQ: TRAX) receives new equity awards - Stock Titan

Director Magda Marquet granted options and RSUs at First Tracks (TRAX) - Stock Titan

Director at First Tracks Biotherapeutics (TRAX) granted options and RSUs - Stock Titan

Director John A. Orwin receives new equity awards at First Tracks Biotherapeutics (TRAX) - Stock Titan

First Tracks (TRAX) awards director 42,000 options and 15,000 RSUs - Stock Titan

Executive equity awards at First Tracks Biotherapeutics (TRAX) detailed - Stock Titan

First Tracks (TRAX) CEO receives new stock options and RSU awards - Stock Titan

First Tracks Biotherapeutics (TRAX) CFO receives new option and RSU awards - Stock Titan

First Tracks Biotherapeutics, Inc. (TRAX) Cash From Financing (TTM) - Zacks Investment Research

First Tracks Biotherapeutics, Inc. (TRAX) Dividend (TTM) - Zacks Investment Research

This First Tracks Biotherapeutics analyst begins coverage on a bullish note; here are top 4 initiations for Monday - MSN

[EFFECT] First Tracks Biotherapeutics, Inc. SEC Filing - Stock Titan

Is AnaptysBio (ANAB) 51.9% Undervalued After Q1 2026 EPS/Revenue - GuruFocus

TRAX Should I Buy - Intellectia AI

AnaptysBio (NASDAQ: ANAB) shifts to royalty focus after Q1 2026 loss - Stock Titan

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire

First Tracks Biotherapeutics, Inc. (TRAX) - Zacks Investment Research

AnaptysBio appoints Christopher Murphy as CFO - MSN

Two new option listings and one option delisting on May 11th - TipRanks

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

First Tracks Biotherapeutics, Inc. (TRAX) Cash From Operations (TTM) - Zacks Investment Research

Biotech royalty manager AnaptysBio brings in dealmaker CFO and new director - Stock Titan

First Tracks Biotherapeutics, Inc. (TRAX) Net Income (TTM) - Zacks Investment Research

TRAX: First Tracks Biotherapeutics, Inc.Interactive Chart - Zacks Investment Research

Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal Outcome - Yahoo Finance

First Tracks Biotherapeutics, Inc. (TRAX) Eps Diluted (TTM) - Zacks Investment Research

First Tracks Biotherapeutics, Inc. (TRAX) Ps Ratio (TTM) - Zacks Investment Research

First Tracks Biotherapeutics, Inc. (TRAX) Debt Equity Ratio (Quarterly) - Zacks Investment Research

First Tracks Biotherapeutics, Inc. (TRAX) Return On Equity (TTM) - Zacks Investment Research

ROIV

$30.41

1.27%

MRNA

$55.40

6.27%

BNTX

$89.50

1.43%

RPRX

$54.21

0.11%

ONC

$263.92

1.60%

RVMD

$156.58

2.17%

야후에서 열기 | 구글에서 열기 | 핀비즈에서 열기 | MarketWatch에서 열기 | EDGAR에서 열기 | 로이터에서 공개